【Hocance Biotech】Announcement of the Company's Q1 2026 Consolidated Financial Report Submitted to the Board of Directors

1. Date of submission to the Board of Directors or resolution by the Board of Directors: 2026/04/28 2. Date of approval by the Audit Committee: 2026/04/28 3. Reporting period of financial statements or annual self-declared financial information: 2026/01/01~2026/03/31 4. Cumulative operating revenue from January 1 to the end of this period (in thousands of NTD): 190,868 5. Cumulative operating gross profit (gross loss) from January 1 to the end of this period (in thousands of NTD): 134,561 6. Cumulative operating profit (loss) from January 1 to the end of this period (in thousands of NTD): 58,409 7. Cumulative pre-tax net profit (net loss) from January 1 to the end of this period (in thousands of NTD): 68,648 8. Cumulative net profit (net loss) for this period from January 1 to the end of this period (in thousands of NTD): 52,793 9. Cumulative net profit (loss) attributable to owners of the parent company from January 1 to the end of this period (in thousands of NTD): 52,793 10. Cumulative basic earnings per share (loss) from January 1 to the end of this period (in NTD): 0.59 11. Total assets at the end of the period (in thousands of NTD): 1,990,823 12. Total liabilities at the end of the period (in thousands of NTD): 364,273 13. Equity attributable to owners of the parent company at the end of the period (in thousands of NTD): 1,626,550 14. Other matters that should be specified: None